Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional Mapping of the Human Cannabinoid Receptor 1 (<i>CNR1</i>) Gene Promoter.

Molecules (Basel, Switzerland)·2026
Same author

Pharmacokinetics of Cannabinoids Delivered by Diverse Routes in Rodents.

Medical cannabis and cannabinoids·2026
Same author

Are Cannabis and/or Cannabinoids a Potential Therapy for ALS?

Muscle & nerve·2026
Same author

Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model.

Bone·2026
Same author

Better together? Individual and synergistic effects of noneuphorigenic cannabinoids on visceral sensation.

The Journal of pharmacology and experimental therapeutics·2025
Same author

The Pharmacology of Cannabinoids in Chronic Pain.

Medical cannabis and cannabinoids·2025

Related Experiment Video

Updated: Jul 14, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Glucocorticoids plus opioids up-regulate genes that influence neuronal function.

Gregg R Ward1, Steven O Franklin, Tonya M Gerald

  • 1Neuroscience of Drug Abuse Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Cellular and Molecular Neurobiology
|June 8, 2007
PubMed
Summary

Glucocorticoids and mu-opioid receptor agonists synergistically up-regulate genes involved in neuronal function. This combined effect, not seen with individual treatments, highlights potential interactions in neuroadaptation.

More Related Videos

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats
09:43

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method
10:53

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method

Published on: February 26, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats
09:43

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method
10:53

Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method

Published on: February 26, 2018

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genomics

Background:

  • Glucocorticoids and opioids are key regulators of neuronal function.
  • Understanding their combined effects on gene expression is crucial for cellular adaptation.
  • Previous research has not fully elucidated the synergistic genomic responses.

Purpose of the Study:

  • To investigate the functional genomics of combined glucocorticoid and opioid receptor stimulation in neuronal cells.
  • To identify genes synergistically regulated by dexamethasone and DAMGO.
  • To explore the implications for neuronal function and neuroadaptation.

Main Methods:

  • Utilized human SH-SY5Y neuroblastoma cells in a cultured neuronal model.
  • Treated cells with dexamethasone, DAMGO, or a combination of both.
  • Analyzed gene expression changes using oligonucleotide-array human gene chips and validated with RT-PCR.

Main Results:

  • Five genes (FRS2, CTNNB1, PRCP, MPHOSPH9, ZFP95) were significantly up-regulated by the combination of dexamethasone and DAMGO, but not by either agent alone.
  • These identified genes are involved in critical neuronal processes like signal transduction and synapse formation.
  • Cell growth rates remained unaffected by the treatments.

Conclusions:

  • Sustained co-stimulation of mu-opioid and glucocorticoid receptors synergistically regulates genes impacting neuronal function.
  • This synergistic regulation may play a role in neuroadaptation to reinforcing drugs under stress.
  • Further in vivo studies are needed to confirm these findings in complex physiological conditions.